> XBB.1.5 strain of Covid CFOTO | Future Publishing | Getty Images The U.S. Food and Drug Administration (FDA) has released a recommendation for Covid vaccine manufacturers to develop single-strain shots for the fall that specifically target the omicron subvariant XBB.1.5. This strain is currently the dominant variant of the virus nationwide. In their official …
House Democrats have called on major retail pharmacies, including Walmart, Costco, Kroger, Safeway, and Health Mart, to publicly commit to selling the prescription abortion pill mifepristone at their retail pharmacies. Currently, pending lawsuits have put mifepristone’s approval in the US at risk, even though it is the most common method for terminating pregnancy in the …
A woman receives a booster dose of the Moderna coronavirus disease (COVID-19) vaccine at a vaccination centre in Antwerp, Belgium, February 1, 2022. Johanna Geron | Reuters The U.S. Food and Drug Administration’s independent panel of advisors on Thursday recommended updating Covid shots for the fall and winter to target one specific variant – the …
Health insurer stocks experienced a decline on Wednesday following a warning from UnitedHealth Group about higher medical costs. The company highlighted that older Americans are starting to catch up on surgeries they delayed during the Covid-19 pandemic (source). As a result, UnitedHealth’s shares, the largest U.S. health-care provider by market value, closed around 6% lower, …
In this illustration photo taken in Krakow, Poland on December 2, 2021, medical syringes and the Novavax logo are prominently displayed in the background. Novavax, a cash-strapped Covid vaccine maker, is confident about its ability to survive and thrive. The Maryland-based company recently announced its first-quarter financial results, which included a cost-cutting initiative and a …
An independent advisory panel to the Food and Drug Administration (FDA) has recommended the approval of nirsevimab, a monoclonal antibody developed by AstraZeneca to protect infants from respiratory syncytial virus (RSV), which is the leading cause of hospitalization among newborns. If approved, nirsevimab would be the first medical intervention available in the U.S. that can …
David Rosario, a restaurant owner from New Jersey, remembers the late 1980s with mixed emotions as he achieved his goal of becoming a professional dancer in New York City in a world where many young male friends lost their lives to AIDS, which hit the gay community especially hard. Today, Rosario picks up medication at …
Eisai and Biogen’s drug Leqembi, aimed at treating Alzheimer’s, has received unanimous support from a panel of independent advisors to the Food and Drug Administration (FDA), indicating full approval is expected this summer. The advisors voted 6-0 in success of Eisai’s data, which showed a substantial clinical benefit for patients. While the FDA is not …